Aegis AcuRiseID™ adherence monitoring assists in the continuous monitoring of a person’s recovery and helps build trust between a prescriber and their patient.
Medication monitoring can be used to detect inappropriate prescription drug or substance use, whether intentional or unintentional, and diversion of prescription medications.
Aegis AcuRiseID™ allows for monitoring progress toward treatment goals and helps prevent human tragedy for those living with substance use disorder.
Testing is available for medication assisted treatment therapies and many medications utilized in the treatment of behavioral health conditions so that clinicians can customize their testing order to the medications and substances most appropriate for monitoring. Testing can be expanded or reduced according to the individual’s risk of adverse outcomes or substance misuse.
Contact us for more information on our complete flexible test menu.
50%
More than one million people have died since 1999 from a drug overdose.11. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2022. Available at http://wonder.cdc.gov.
48.7 MIL.
In 2022, 48.7 million people aged 12 or older (or 17.3%) had a substance use disorder (SUD) in the past year.22. https://www.samhsa.gov/newsroom/press-announcements/20231113/hhs-samhsa-release-2022-nsduh-data#
Adherence to medication assisted treatment is associated with fewer relapses, nonfatal overdoses, hospitalizations and ER visits.3,43. Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018;9:59-78. Published 2018 Sep 21. doi:10.2147/SAR.S150253
4. Kinsky S, Houck PR, Mayes K, Loveland D, Daley D, Schuster JM. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective. J Subst Abuse Treat. 2019;104:15-21. doi:10.1016/j.jsat.2019.05.015
“Individuals that are in my care often have multiple substance use disorders. In treating these individuals, it is important to be able to objectively identify what is being used in order to augment treatment.”
Stacey Groves, Physician Assistant
Freeman Recovery
Burns, TN
Aegis offers specialized services that help provide additional insight into a patient’s clinical picture:
BioDetect™
BioDetect testing assists providers in identification of urine substitution with a non-biologic specimen, including things like synthetic urine and is included in testing on all urine specimens.
InterACT Rx™
InterACT Rx testing, when used alongside definitive testing to assess prescription and non-prescription substance use, can improve care decisions through objective detection of ingested substances capable of contributing to drug-drug interactions and adverse drug events (ADEs).
Novel Psychoactive Substance (NPS) Testing
Patients may seek additional therapy for pain or anxiety or may look for recreational use of substances they believe cannot be detected by traditional toxicology testing. Aegis’s Novel Psychoactive Substance testing can reveal the use of many designer drugs, some of which may even be unknown to the patient.
Clinical Testing
Depending on the type of care provided at a given practice site, additional clinical blood testing services can help with continuity of care. Contact your local Aegis representative to find out if these services are a good fit for your practice.
- BioDetect™
-
BioDetect™
BioDetect testing assists providers in identification of urine substitution with a non-biologic specimen, including things like synthetic urine and is included in testing on all urine specimens.
- InterACT Rx™
-
InterACT Rx™
InterACT Rx testing, when used alongside definitive testing to assess prescription and non-prescription substance use, can improve care decisions through objective detection of ingested substances capable of contributing to drug-drug interactions and adverse drug events (ADEs).
- Novel Psychoactive Substance (NPS) Testing
-
Novel Psychoactive Substance (NPS) Testing
Patients may seek additional therapy for pain or anxiety or may look for recreational use of substances they believe cannot be detected by traditional toxicology testing. Aegis’s Novel Psychoactive Substance testing can reveal the use of many designer drugs, some of which may even be unknown to the patient.
- Clinical Testing
-
Clinical Testing
Depending on the type of care provided at a given practice site, additional clinical blood testing services can help with continuity of care. Contact your local Aegis representative to find out if these services are a good fit for your practice.
